Clinical trials: Unspecified Schizophrenia Spectrum and Other Psychotic Disorder
Schizophrenia
Assessment of the Efficacy of a Fatigue Management Therapy in Schizophrenia
Fatigue is commonly experienced in numerous pathologies, including schizophrenia. Research has shown that chronic fatigue can exacerbate clinical symptoms.
- Trial name
- ENERGY (NCT04332601)
- Testing
- Fatigue Management Therapy, TAU (Treatment as usual)
- Volunteers
- 200 people
- Sponsor
- University Hospital, Montpellier
Social Interaction, Schizophrenia Spectrum and Other Psychotic Disorders
Personalizing Interventions Using Real-World Interactions
Social functioning deficits are among the most disabling and difficult to treat aspects of schizophrenia. An essential component of social functioning is metacognition-a process that is profoundly disrupted in schizophrenia and…
- Trial name
- NCT04665401
- Testing
- Tailored MERIT, Standard MERIT
- Volunteers
- 34 people
- Sponsor
- Indiana University
Schizophrenia, Schizoaffective Disorder
Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia
Schizophrenia is marked by problems in attention, memory and problem solving. These deficits predict long-term functional outcome such as the ability to live independently and maintain employment, but they are not ameliorated by…
- Trial name
- NCT02069392
- Testing
- Cognitive remediation training, Nicotine polacrilex lozenge
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Schizoaffective Disorder
Selective Estrogen Receptor Modulators for Women of Child-bearing Age With Schizophrenia
The aim of the project is to investigate the use of Raloxifene (a new form of estrogen) in the treatment of young women with schizophrenia and schizoaffective disorder.
- Trial name
- NCT02354001
- Testing
- Raloxifene hydrochloride
- Where
- Australia
- Volunteers
- 80 people
- Sponsor
- The Alfred
Schizophrenia
A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs
The purpose of this study is to compare the efficacy and safety of ziprasidone and clozapine in schizophrenic patients who are resistant and/or intolerant to antipsychotic treatment
- Trial name
- MOZART (NCT00649844)
- Testing
- Clozapine, Ziprasidone
- Where
- 22 sites in Italy
- Volunteers
- 147 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Psychotic Disorders
A Comparison of Cognitive Training Approaches in Psychotic Disorders
Cognitive remediation (CR) is the best treatment to improve neurocognitive abilities for individuals with psychosis, however, there is no gold standard method of cognitive remediation available.
- Trial name
- NCT03024203
- Testing
- Cognitive Remediation - Executive Training, Cognitive Remediation - Perceptual Training
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Queen's University
Schizophrenia
Energy Homeostasis Under Treatment With Atypical Antipsychotics
The purpose of this study is to evaluate the effects of different atypical antipsychotics on weight changes, energy homeostasis, metabolism, energy intake as well as activity.
- Trial name
- NCT00148564
- Testing
- olanzapine, Ziprasidone
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Charite University, Berlin, Germany
Refractory Schizophrenia
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
This is an adaptive, Phase II/III study in 2 parts (i.e. Part 1 (dose ranging) and Part 2 (Hypothesis testing)). NaBen® is granted Breakthrough Therapy Designation by US FDA as treatment for refractory schizophrenia.
- Trial name
- NCT03094429
- Testing
- NaBen®
- Where
- United States
- Volunteers
- 287 people
- Sponsor
- SyneuRx International (Taiwan) Corp
Psychological Stresses
Strengths-Based Family Psychoeducation for Youth Psychosis
The onset of Psychosis forces family members to bear a heavy burden of care. The mental well-being of the family is so complicated that it is important to relieve their psychological stresses.
- Trial name
- NCT01731977
- Testing
- Strengths-based family psychoeducation
- Where
- 4 sites in Japan
- Volunteers
- 74 people
- Sponsor
- Nagoya City University
Psychotic Disorders
Optimal Duration of Early Intervention for Psychosis
A total of 160 subjects, who aged 18-35 and had completed the first 2 years of case management in the EASY programme will be randomized in 1:1 ratio into either (1) receiving an additional year of case management, or (2)…
- Trial name
- NCT01202357
- Testing
- Community Case Management
- Where
- China
- Volunteers
- 160 people
- Sponsor
- The University of Hong Kong
Schizophrenia
Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia
The purpose of this study is to assess the safety, pharmacokinetics and efficacy of 3 fixed doses of MP-214 orally administered once daily to patients with schizophrenia.
- Trial name
- NCT00862992
- Testing
- Cariprazine 3 mg, Cariprazine 6 mg, Cariprazine 12.5 mg
- Where
- Japan
- Volunteers
- 34 people
- Sponsor
- Tanabe Pharma Corporation
Schizophrenia and Schizoaffective Disorder
A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices
The purpose of this clinical research study is to evaluate the overall effectiveness of 8 week of aripiprazole treatment.
- Trial name
- NCT00292409
- Testing
- Aripiprazole
- Volunteers
- 400 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Epilepsy
A Drug Interaction Study of Valproic Acid and Single-dose Paliperidone Extended-Release (ER) in Healthy Men
The purpose of this study is to evaluate the effect of valproic acid (VPA) on the pharmacokinetics (blood levels) of a single oral dose of an extended-release formulation of paliperidone in healthy male volunteers.
- Trial name
- NCT01060228
- Testing
- paliperidone ER, divalproex sodium ER
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Bipolar Disorder
Impact of Cognitive & Metacognitive Performance on Knowledge Learning When Conducting Therapeutic Education Programs
People with schizophrenia and bipolar disorder display alterations in cognition and metacognition. These alterations may have an impact on learning during therapeutic education programs.
- Trial name
- MetaCOGNITION (NCT04590300)
- Testing
- QUESTIONNAIRES
- Where
- France
- Volunteers
- 108 people
- Sponsor
- Centre Hospitalier Charles Perrens, Bordeaux
Schizophrenia, Bipolar Disorder
App and Body Fat Scale in the Management of Overweight Patients
This study tests whether using a health app (Huawei Health) and a smart body fat scale can help overweight patients with schizophrenia or bipolar disorder lose weight and stay engaged in their health. What We're Testing: 1.
- Conditions
- Schizophrenia, Bipolar Disorder, Metabolic Syndrome, Overweight and Obesity
- Trial name
- NCT05866107
- Testing
- Effectiveness and Feasibility of Self-Monitoring for Weight Management in Individuals with Mental Disorders Using Digital Intervention ("SWIM" trial)
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Capital Medical University
Tobacco Use Disorder, Schizophrenia
Combining rTMS With Varenicline to Prevent Smoking Lapse in Schizophrenia
Tobacco smokers with schizophrenia are known to be resistant smokers, with high rates of smoking and inability to quit in the long-term, often related to smoking relapse.
- Conditions
- Tobacco Use Disorder, Schizophrenia, Cognitive Functioning, Craving
- Trial name
- NCT03497299
- Testing
- Active rTMS (20Hz)
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia Spectrum and Other Psychotic Disorders
A Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults
Immunological factors are assumed to be determinants for some psychiatric disorders, thus anti-inflammatory drugs may be helpful. However, studies on such treatments are scarce.
- Trial name
- RCT-RITS (NCT05622201)
- Testing
- Rituximab
- Where
- Sweden
- Volunteers
- 123 people
- Sponsor
- Region Örebro County
Schizophrenia and Schizoaffective Disorder
A Trial of Group Cognitive Behavioral Therapy for Psychosis (the Feeling Safe Programme)
Schizophrenia is a serious psychiatric disorder characterized by delusions, hallucinations, negative symptoms and disorganized behaviour.
- Trial name
- NCT07408934
- Testing
- Cognitive Behavioral Therapy for Psychosis
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- The Royal Ottawa Mental Health Centre
Schizophrenia
The Effectiveness and Efficacy of the Combination of the Integrated Psychological Therapy and Metacognitive Training.
The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia. Is it effective and efficacious?
- Trial name
- ATHSCHIZ (NCT05623228)
- Testing
- The combination of the Integrated Psychological Therapy and Metacognitive Training in individuals with schizophrenia and treatment resistant schizophrenia
- Where
- Greece
- Volunteers
- 35 people
- Sponsor
- Rakitzi, Stavroula
Treatment-resistant Schizophrenia
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
This is a prospective, 12-week, randomized, double-blind, placebo-controlled study, designed to evaluate the efficacy, safety, and tolerability of a dose of evenamide of 15 mg bid, compared to placebo, as add-on treatment in…
- Trial name
- ENIGMA-TRS 2 (NCT07184619)
- Testing
- Evenamide 15 mg bid
- Where
- 19 sites in United States, Argentina and 2 more
- Volunteers
- 400 people
- Sponsor
- Newron Pharmaceuticals SPA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.